In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …

CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of
patients with refractory B-cell neoplasms. However, despite having unprecedented efficacy …

Chimeric antigen receptor (CAR) therapy is a promising immunotherapeutic strategy for
treating multiple refractory blood cancers, but further advances are required for solid tumor …

Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …

Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have
revolutionized treatment for several cancer types over the past decade. Despite this success …

Equipping cancer-fighting immune cells with chimeric antigen receptor (CAR) has gained
immense attention for cancer treatment. CAR-engineered T cells (CAR T cells) are the first …

Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …

Natural killer cells constitute a part of the innate immune system that mediates an effective
immune response towards virus-infected and malignant cells. In recent years, research has …

Advancements in adoptive cell therapy over the last four decades have revealed various
new therapeutic strategies, such as chimeric antigen receptors (CARs), which are dedicated …

Antigen presentation defects in tumors are prevalent mechanisms of adaptive immune
evasion and resistance to cancer immunotherapy, whereas how tumors evade innate …